{"id":69563,"date":"2026-07-08T13:40:06","date_gmt":"2026-07-08T05:40:06","guid":{"rendered":"https:\/\/flcube.com\/?p=69563"},"modified":"2026-07-08T13:40:07","modified_gmt":"2026-07-08T05:40:07","slug":"sino-biopharmaceutical-expands-gsk-partnership-to-commercialize-trelegy-and-anoro-ellipta-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69563","title":{"rendered":"Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) announced an expanded strategic partnership with <strong>GlaxoSmithKline plc<\/strong> (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) to commercialize two key respiratory therapies\u2014<strong>Trelegy Ellipta<\/strong> (fluticasone furoate\/umeclidinium\/vilanterol, or FF\/UMEC\/VI) and <strong>Anoro Ellipta<\/strong> (umeclidinium\/vilanterol, or UMEC\/VI)\u2014across mainland China through its subsidiary <strong>Chia Tai Tianqing<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-commercial-terms\" class=\"wp-block-heading\">Deal Structure &amp; Commercial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Sino Biopharmaceutical (via Chia Tai Tianqing) \/ GlaxoSmithKline<\/td><\/tr><tr><td><strong>Products<\/strong><\/td><td>Trelegy Ellipta (triple therapy), Anoro Ellipta (dual bronchodilator)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China<\/td><\/tr><tr><td><strong>Term<\/strong><\/td><td>Initial 5.5 years, extendable by mutual consent<\/td><\/tr><tr><td><strong>Supply Model<\/strong><\/td><td>GSK manufactures and supplies products to Chia Tai Tianqing<\/td><\/tr><tr><td><strong>Revenue Recognition<\/strong><\/td><td>Sales recognized as GSK revenue<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>8 July 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-portfolio-amp-market-position\" class=\"wp-block-heading\">Product Portfolio &amp; Market Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trelegy Ellipta<\/strong>: Currently the <strong>only single-inhaler triple therapy<\/strong> approved in China for both <strong>chronic obstructive pulmonary disease (COPD)<\/strong> and <strong>asthma<\/strong>, combining an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and long-acting beta-agonist (LABA) in one device.<\/li>\n\n\n\n<li><strong>Anoro Ellipta<\/strong>: A <strong>dual bronchodilator<\/strong> combining LAMA and LABA components, indicated specifically for <strong>COPD maintenance treatment<\/strong>, offering improved lung function and symptom control compared to monotherapy.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">China represents one of the world&#8217;s largest respiratory disease markets, with an estimated <strong>100 million COPD patients<\/strong> and growing asthma prevalence, creating significant commercial opportunity for premium branded therapies with established clinical profiles.<\/p>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-impact\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Impact<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>For Sino Biopharmaceutical<\/strong>: The partnership leverages Chia Tai Tianqing&#8217;s extensive commercial infrastructure, hospital access network, and respiratory therapeutic expertise to drive adoption of premium international brands while diversifying beyond its traditional oncology and hepatology portfolio.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>For GSK<\/strong>: The arrangement maintains GSK&#8217;s revenue recognition while benefiting from local partner expertise in navigating China&#8217;s complex healthcare landscape, including hospital formulary inclusion, provincial tender processes, and physician education initiatives.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The collaboration builds on the companies&#8217; existing relationship and reflects the broader trend of multinational pharmaceutical companies partnering with well-capitalized Chinese firms to optimize market access while retaining financial upside.<\/p>\n\n\n\n<h2 id=\"h-financial-amp-operational-outlook\" class=\"wp-block-heading\">Financial &amp; Operational Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Attribution<\/strong>: All product sales will be recorded as <strong>GSK revenue<\/strong>, with Chia Tai Tianqing earning commercialization fees or margins on distribution.<\/li>\n\n\n\n<li><strong>Market Penetration Strategy<\/strong>: Chia Tai Tianqing will deploy its 3,000+ field force to target tier-1 and tier-2 hospitals initially, with expansion to tier-3 facilities based on reimbursement status and formulary approvals.<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: The partnership positions the companies against domestic generic entrants and other multinational respiratory portfolios, with Trelegy&#8217;s unique triple-therapy positioning providing a key differentiator.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking information regarding commercial partnerships, market opportunities, and strategic initiatives. Actual results may differ materially due to regulatory changes, competitive dynamics, reimbursement decisions, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Limited (HKG: 1177) announced an expanded strategic partnership with GlaxoSmithKline plc (GSK, NYSE:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[661,278,184,908,914,313],"class_list":["post-69563","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-chia-tai-tianqing-pharmaceutical","tag-glaxosmithkline","tag-gsk","tag-hkg-1177","tag-nyse-gsk","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced an expanded strategic partnership with GlaxoSmithKline plc (GSK, NYSE: GSK) to commercialize two key respiratory therapies\u2014Trelegy Ellipta (fluticasone furoate\/umeclidinium\/vilanterol, or FF\/UMEC\/VI) and Anoro Ellipta (umeclidinium\/vilanterol, or UMEC\/VI)\u2014across mainland China through its subsidiary Chia Tai Tianqing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69563\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced an expanded strategic partnership with GlaxoSmithKline plc (GSK, NYSE: GSK) to commercialize two key respiratory therapies\u2014Trelegy Ellipta (fluticasone furoate\/umeclidinium\/vilanterol, or FF\/UMEC\/VI) and Anoro Ellipta (umeclidinium\/vilanterol, or UMEC\/VI)\u2014across mainland China through its subsidiary Chia Tai Tianqing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69563\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-08T05:40:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-08T05:40:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69563#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69563\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China\",\"datePublished\":\"2026-07-08T05:40:06+00:00\",\"dateModified\":\"2026-07-08T05:40:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69563\"},\"wordCount\":439,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Chia Tai Tianqing Pharmaceutical\",\"GlaxoSmithKline\",\"GSK\",\"HKG: 1177\",\"NYSE: GSK\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69563#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69563\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69563\",\"name\":\"Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-08T05:40:06+00:00\",\"dateModified\":\"2026-07-08T05:40:07+00:00\",\"description\":\"Sino Biopharmaceutical Limited (HKG: 1177) announced an expanded strategic partnership with GlaxoSmithKline plc (GSK, NYSE: GSK) to commercialize two key respiratory therapies\u2014Trelegy Ellipta (fluticasone furoate\\\/umeclidinium\\\/vilanterol, or FF\\\/UMEC\\\/VI) and Anoro Ellipta (umeclidinium\\\/vilanterol, or UMEC\\\/VI)\u2014across mainland China through its subsidiary Chia Tai Tianqing.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69563#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69563\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69563#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced an expanded strategic partnership with GlaxoSmithKline plc (GSK, NYSE: GSK) to commercialize two key respiratory therapies\u2014Trelegy Ellipta (fluticasone furoate\/umeclidinium\/vilanterol, or FF\/UMEC\/VI) and Anoro Ellipta (umeclidinium\/vilanterol, or UMEC\/VI)\u2014across mainland China through its subsidiary Chia Tai Tianqing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69563","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China","og_description":"Sino Biopharmaceutical Limited (HKG: 1177) announced an expanded strategic partnership with GlaxoSmithKline plc (GSK, NYSE: GSK) to commercialize two key respiratory therapies\u2014Trelegy Ellipta (fluticasone furoate\/umeclidinium\/vilanterol, or FF\/UMEC\/VI) and Anoro Ellipta (umeclidinium\/vilanterol, or UMEC\/VI)\u2014across mainland China through its subsidiary Chia Tai Tianqing.","og_url":"https:\/\/flcube.com\/?p=69563","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-08T05:40:06+00:00","article_modified_time":"2026-07-08T05:40:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69563#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69563"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China","datePublished":"2026-07-08T05:40:06+00:00","dateModified":"2026-07-08T05:40:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69563"},"wordCount":439,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Chia Tai Tianqing Pharmaceutical","GlaxoSmithKline","GSK","HKG: 1177","NYSE: GSK","Sino Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69563#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69563","url":"https:\/\/flcube.com\/?p=69563","name":"Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-08T05:40:06+00:00","dateModified":"2026-07-08T05:40:07+00:00","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced an expanded strategic partnership with GlaxoSmithKline plc (GSK, NYSE: GSK) to commercialize two key respiratory therapies\u2014Trelegy Ellipta (fluticasone furoate\/umeclidinium\/vilanterol, or FF\/UMEC\/VI) and Anoro Ellipta (umeclidinium\/vilanterol, or UMEC\/VI)\u2014across mainland China through its subsidiary Chia Tai Tianqing.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69563#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69563"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69563#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69563"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69563\/revisions"}],"predecessor-version":[{"id":69566,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69563\/revisions\/69566"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}